Related Experiment Videos
Shear Wave Elastography Combined With Ki67 Predicting Pathological Complete Response in Invasive Breast Cancer After
1Department of Ultrasound, Second Affiliated Hospital of Shandong First Medical University, Tai'an, China.
Journal of Clinical Ultrasound : JCU
|July 31, 2026
Summary
Shear wave elastography (SWE) combined with Ki67 and tumor size changes effectively predicts pathological complete response (pCR) in breast cancer after neoadjuvant chemotherapy (NAC). This integrated approach offers superior accuracy for assessing treatment outcomes compared to individual markers.
Area of Science:
- Oncology
- Radiology
- Medical Imaging
Background:
- Accurate prediction of pathological complete response (pCR) in invasive breast cancer following neoadjuvant chemotherapy (NAC) is crucial for treatment stratification.
- Traditional methods for assessing treatment response have limitations in predicting pCR accurately.
Purpose of the Study:
- To investigate the clinical relevance of shear wave elastography (SWE) combined with Ki67 expression for predicting pCR in invasive breast cancer after NAC.
- To evaluate the diagnostic performance of individual parameters and a composite model in assessing pCR.
Main Methods:
- Retrospective analysis of 167 breast cancer patients treated with NAC.
- Comparison of clinical data, changes in tumor diameter (ΔD), Ki67 expression (ΔKi67), and SWE measurements (SWEmax, 2mm shell SWEmax, ΔSWEmax) between pCR and non-pCR groups.
- Multivariate logistic regression and ROC curve analysis were used to assess predictive values.
Main Results:
- Greater changes in ΔD and ΔKi67 were observed in the pCR group.
- Post-NAC SWEmax was lower, while ΔSWEmax (tumor and 2mm shell) was higher in the pCR group, with significant differences (p<0.05).
- A composite model combining ΔD, ΔKi67, ΔSWEmax, and 2mm shell ΔSWEmax achieved a high AUC of 0.926 for pCR prediction, outperforming individual parameters.
Conclusions:
- Changes in tumor size, Ki67 expression, and SWE parameters (both pre- and post-NAC) independently influence pCR prediction in breast cancer.
- A composite predictive model incorporating these parameters demonstrates high discriminatory ability for assessing pCR post-NAC.
- The validated model shows promising clinical utility for evaluating the ultimate pathological response to neoadjuvant chemotherapy.